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What’s new? (75 words, max. 75) 
Data on invasive cervical cancer (ICC) incidence in HIV-positive women and the effect of cervical 
cancer screening in sub-Saharan Africa are scarce. This South African cohort analysis found that ICC 
incidence substantially decreased after the implementation of a Pap-based screening program and 
improved access to treatment of cervical lesions. However, ICC risk remained high in women who 
initiated ART at low CD4 cell counts. Patient-level monitoring of  screening programs is essential to 
improve ICC prevention. 
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Abstract (248 max. 250, unstructured) 
Data on invasive cervical cancer (ICC) incidence in HIV-positive women and the effect of cervical cancer 
screening in sub-Saharan Africa are scarce. We estimated i) ICC incidence rates in women (≥18 years) 
who initiated antiretroviral therapy (ART) at the Themba Lethu Clinic (TLC) in Johannesburg, South 
Africa, between 2004-2011; and ii) the effect of a Pap-based screening program. We included 10,640 
women; median age at ART initiation: 35 years (interquartile range [IQR] 30-42), median CD4 count at 
ART initiation: 113 cells/µl (IQR 46-184). During 27,257 person-years (pys), 138 women were diagnosed 
with ICC; overall incidence rate: 506/100,000 pys (95% CI 428-598). The ICC incidence rate was highest 
(615/100,000 pys) in women who initiated ART before cervical cancer screening became available in 
04/2005, and was lowest (260/100,000 pys) in women who initiated ART from 01/2009 onwards when 
the cervical cancer screening program and access to treatment of cervical lesions was expanded 
(adjusted hazard ratio [aHR] 0.42, 95% confidence interval [CI] 0.20-0.87). Advanced HIV/AIDS stage (4 
versus 1, aHR 1.95, 95% CI 1.17-3.24) and middle age at ART initiation (36-45 versus 18-25 years, aHR 
2.51, 95% CI 1.07-5.88) were risk factors for ICC. The ICC incidence rate substantially decreased with 
the implementation of a Pap-based screening program and improved access to treatment of cervical 
lesions. However, the risk of developing ICC after ART initiation remained high. To inform and improve 
ICC prevention and care for HIV-positive women in sub-Saharan Africa, implementation and 
monitoring of cervical cancer screening programs are essential.  
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Introduction 
Invasive cervical cancer (ICC) is an AIDS-defining malignancy associated with high-risk types of human 
papillomavirus (HPV) infection.1 HIV-positive women have a higher risk of co-infection with high-risk 
HPV types, HPV reactivation, persistence of cytological abnormalities and more rapid progression to 
ICC.2–8 In South Africa, where one in every four adult women (15-49 years) have HIV,9 ICC is the second 
most common cancer in women in the general population and the leading cause of cancer-related 
deaths.10 
The effect of antiretroviral therapy (ART) on the incidence of cervical lesions and ICC in HIV-positive 
women remains unclear.11–14 On one hand, early initiation of ART may reduce the risk of coinfection 
with high-risk HPV types.15 On the other hand, ART might lead to higher ICC incidence rates due to 
lower competing mortality from other HIV-related causes.11 Therefore, effective cervical cancer 
screening programs are essential to lower ICC-related morbidity and mortality in HIV-positive 
women.16 Because of the increased risk of developing ICC, more frequent cervical cancer screening is 
recommended for HIV-positive than for HIV-negative women.17,18 To inform cervical cancer screening 
programs for HIV-positive women in South Africa, data on ICC burden, associated risk factors, and the 
effect of screening programs on ICC risk in this specific population are needed. Whereas some ICC 
incidence rate estimates are available for HIV-positive women in sub-Saharan Africa, ranging from 
8/100,000 pys to 259/100,000 pys,19–22 data on risk factors and the effect of cervical cancer screening 
on ICC risk are scarce for the African setting. Studies examining the effect of cervical cancer screening 
at the patient-level often do not have enough power to detect changes in ICC incidence rates.13,15  
However, relevant information can also be obtained from using precancerous lesions as an endpoint. 
We estimated ICC incidence rates in HIV-positive women who initiated ART at the Themba Lethu Clinic 
(TLC) in Johannesburg, South Africa, identified risk factors for developing ICC in these women, and 
assessed the effect of the introduction and expansion of a Papanicolaou (Pap) smear based cervical 
cancer screening program on ICC incidence rates.  
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Methods 
Study site and data sources 
The TLC in Johannesburg, South Africa, was established in 1992 to provide care for HIV-positive adults 
living in the area. It is a government clinic, but also receives financial support from Right to Care, a 
South African non-profit organization, which is partly funded by the United States Agency for 
International Development (USAID) and the President’s Emergency Plan for AIDS Relief (PEPFAR) 
program. Since 2004, the TLC cohort prospectively captures clinical, demographic, laboratory and 
treatment data collected as part of routine care.23 This routine data is captured at enrolment and each 
follow-up visit and is stored electronically. Follow-up visits are typically scheduled one, three, six, and 
12 months after ART start and yearly thereafter. Since April 2005 HIV-positive women are screened for 
abnormal cytological findings of the cervix using conventional Pap tests as liquid based cytology is not 
available in the South African public health sector. In 2009, the Pap-based cervical cancer screening 
program established at the TLC was extended beyond the inception site to further HIV clinics in the 
area, and loop electrical excision procedure (LEEP) became available for treatment of high-grade 
cervical lesions in screened women. In line with the guidelines of the South African National 
Department of Health,18 Pap tests are supposed to be repeated every three years if cytology results 
are normal and after one year if a low-grade cervical squamous intraepithelial lesion is detected in HIV-
positive women. Women with high-grade intraepithelial lesions are supposed to be referred for 
colposcopy. In 2011, data from the TLC cohort were linked to the South African National Cancer 
Registry (NCR) database to complete cancer case recording for patients enrolled in the TLC cohort. The 
NCR is pathology-based and collects information on histologically, cytologically or haematologically 
confirmed cancer cases from both public and private laboratories all over South Africa. The record 
linkage was probabilistic and based on first name, second name, surname, date of birth, and gender. 
Data from the cancer registry were available up to August 2011. To minimize the risk of mismatches 
cancer cases identified through the probabilistic record linkage with the NCR were cross-checked for 
plausibility with patient files from the TLC. The TLC cohort has an on-going ethics approval (M140201) 
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from the Human Research Ethics Committee (Medical) (HREC) of the University of the Witwatersrand 
to analyse routine clinical data, and this approval is renewed annually. The record linkage between the 
TLC cohort database and the NCR in South Africa was based on an additional HREC-approved protocol 
(M110324). Ethical approval was obtained specifically for the current project from the HREC 
(M150215), the London School of Hygiene and Tropical Medicine (LSHTM) MSc Research Ethics 
Committee (Ref. 8948), and the Cantonal Ethics Committee (KEK) Bern (Ref. 028/15). 
Inclusion criteria and definitions 
We included all HIV-positive women aged 18 years or older who initiated ART at the TLC between April 
2004 when the national ART program was initiated in South Africa and August 2011 when the record 
linkage with the NCR was performed. Women who started ART before enrolment into the cohort and 
women without follow-up time on ART, including those diagnosed with ICC before starting ART, were 
excluded. Database closure was set at time of record linkage with the NCR (31st August 2011). Calendar 
time was categorized into three periods to reflect the initiation and extension of Pap-based cervical 
cancer screening, i.e. 04/2004-03/2005 without cervical cancer screening at TLC, 04/2005-12/2008 
with Pap-based cervical cancer screening at TLC, and 01/2009-08/2011 when Pap-based cervical 
cancer screening was extended beyond TLC and LEEP became available. ART was defined as a regimen 
of at least three antiretroviral drugs of any of the following drug classes: nucleoside reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), or protease 
inhibitors (PIs). Regimens consisting of two NRTIs and one NNRTI were classified as NNRTI-based, 
regimens consisting of two NRTIs and one PI (with or without ritonavir as a booster) were classified as 
PI-based. Women were assumed to stay on ART once started. CD4 cell counts at ART initiation were 
defined as the measurement closest to the date of ART initiation, within 90 days before to seven days 
after ART initiation. Nadir CD4 was defined as the lowest ever measured CD4 cell count before ICC 
diagnosis. ICC cases diagnosed before or at start of ART were excluded as prevalent cases, whereas ICC 
cases diagnosed after ART initiation were analysed as incident cases.  
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Statistical analyses 
We calculated ICC incidence rates by dividing the number of women who were diagnosed with ICC 
after ART initiation by the total person-time at risk. Time at risk was measured from ART initiation to 
ICC diagnosis, last follow-up visit, death, or database closure, whichever occurred first. We calculated 
ICC incidence rates for the whole observation time, but also separately for different time periods after 
ART initiation (0 to 1 year, >1 to 3 years, and >3 years after ART initiation). We computed age-
standardized ICC incidence rates using the world standard population proposed by Segi24 and adapted 
by Doll and colleagues.25 As our study population did not include children and only few elderly women, 
we assumed that all women aged ≥60 years had the same ICC incidence rate and that children had an 
ICC incidence rate of  zero. In a sensitivity analysis, we restricted the world standard population to 
adults. We examined potential risk factors for incident ICC using crude and adjusted Cox proportional 
hazards models. We explored the following potential risk factors: age at ART initiation (18-25 years, 
26-35 years, 36-45 years, ≥46 years), current (time-updated) age (18-25 years, 26-35 years, 36-45 
years, ≥46 years), employment status (unemployed versus employed), body mass index (BMI) at ART 
start (<18.5, 18.5-24.9, ≥25 kg/m2), smoking status (never smoked/ever smoked), first-line ART 
regimen (NNRTI-based, PI-based, other ART), calendar period of ART initiation (04/2004-03/2005, 
04/2005-12/2008, 01/2009-08/2011), calendar period of follow-up (04/2004-03/2005, 04/2005-
12/2008, 01/2009-08/2011), WHO clinical stage of HIV/AIDS at ART initiation (1, 2, 3, 4), CD4 cell count 
at ART start (<50, 50-99, 100-199, ≥200 cells/µl), nadir CD4 (<50, 50-99, 100-199, ≥200 cells/µl), current 
(time-updated) CD4 cell count (<100, 100-199, 200-349, 350-499, ≥500 cells/µl), and haemoglobin at 
ART initiation (<10.0, 10.0-11.9, ≥12.0 g/dl). As women with prevalent ICC were excluded from the 
analysis, WHO stage 4 at ART initiation was based on other stage-defining co-morbidities than ICC. We 
also included CD4 cell counts as spline variables in the model. The multivariable Cox model included 
all variables that were significantly or borderline significantly associated with ICC risk in univariable 
analyses, that is age at ART initiation, first-line ART regimen, calendar period of ART initiation, and 
WHO clinical stage of HIV/AIDS at ART initiation. The significance level was set at p-value < 0.05 for all 
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hypothesis tests.  In sensitivity analyses we excluded ICC cases diagnosed within six months after ART 
initiation and women with less than six months of follow-up to reduce potential misclassification of 
prevalent ICC cases as incident ICC cases, and we used multiple imputations for missing data on CD4 
cell counts and WHO stage on HIV/AIDS at ART initiation. We used predictive mean matching and 
chained equations to create 20 imputed datasets. Results are presented as percentages, medians with 
interquartile ranges (IQR), incidence rates per 100,000 pys with 95% confidence intervals (CIs), or 
hazard ratios (HRs) with 95% CIs. All analyses were done in Stata 13.1 (Stata Corporation, College 
Station, Texas, USA). 
 
Results 
Study population 
The TLC dataset included information on 13,383 HIV-positive women aged 18 years or older who 
initiated ART at the TLC between 1st April 2004 and 31st August 2011. Of these we excluded 1,936 
women who started ART before enrolment into the cohort. Another 807 women were excluded for 
reasons detailed in Figure 1. Excluded women were slightly younger (median age: 33 years versus 35 
years) and more likely to receive PI-based first-line ART regimens (14% versus 8%) than included 
women. Data on WHO clinical HIV/AIDS stage and CD4 cell counts at ART initiation were missing for 
the majority of excluded women (68% and 43%, respectively), but for less than 15% of included 
women, and could therefore not be compared. 
We included data on 10,640 women; median age at ART initiation was 35 years (IQR 30-42 years), 
median CD4 cell count at ART initiation was 113 cells/µl (IQR 46-184 cells/µl). Over calendar period, 
the median CD4 cell count at ART initiation increased from 82 cells/µl (IQR 36-143 cells/µl) in 04/2005-
03/2005 to 140 cells/µl (IQR 66-210 cells/µl) in 01/2009-08/2011. About 10% of the included women 
(n=1,021) initiated ART in WHO clinical stage 4, and most women (n=9,785; 92%) received an NNRTI-
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based first-line regimen. About half of the women were unemployed (53%, n=5,646) and the majority 
had never smoked (83%, n=8,823).  
ICC incidence rates and risk factors 
During a total of 27,257 pys, 138 women were diagnosed with ICC for an overall ICC incidence rate of 
506/100,000 pys (95% CI 428-598). The age-standardized ICC incidence rate was 273/100,000 pys (95% 
CI 177-420) when including children and 396/100,000 (95% CI 256-614) when excluding children. 
Median follow-up time after ART initiation was 2.1 years (IQR 0.7-4.1 years), and median time to ICC 
diagnosis after ART start was 1.8 years (IQR 0.9-3.2 years). The ICC incidence rate did not change over 
time after ART initiation (Figure 2). The ICC incidence rate declined over calendar time of ART initiation: 
it was highest (615/100,000 pys) in women who initiated ART before Pap-based screening became 
available at TLC in April 2005, and it was lowest (260/100,000 pys) in women who initiated ART from 
2009 onwards when LEEP became available and Pap-based cervical cancer screening was expanded 
beyond TLC to other HIV clinics in the area, see table 1. No decrease in ICC incidence rates was apparent 
when we looked at calendar period of follow-up instead of calendar period of ART initiation. When we 
excluded the first six months of follow-up after ART initiation in a sensitivity analysis, the ICC incidence 
rate remained similar in the earlier calendar periods of ART initiation, but declined to 69/100,000 pys 
in the most recent calendar period of ART initiation (Supplementary table S1). 
In univariable analyses, the risk of developing ICC was associated with calendar period of ART initiation 
(p = 0.011), age at ART initiation (p = 0.031), first-line ART regimen (p = 0.003), and WHO clinical stage 
of HIV/AIDS at ART initiation (p = 0.059), see table 1. However, CD4 cell count at ART initiation, nadir 
CD4 and current CD4 cell count had no effect on ICC risk in our analyses, neither as categorical variables 
nor as spline variables (data on file). We also did not find an association between ICC risk and calendar 
period of follow-up, employment status, BMI at ART initiation, smoking status, and haemoglobin at 
ART initiation.  
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In adjusted analyses, the risk of developing ICC decreased over calendar period of ART initiation: 
women who initiated ART from 2009 onwards had a 58% lower risk of developing ICC than women 
who initiated ART before April 2005 (adjusted HR 0.42, 95% CI 0.20-0.87). When we excluded the first 
six months of follow-up after ART initiation and all ICC cases diagnosed within this period, ICC risk was 
89% lower (adjusted HR 0.11, 95% CI 0.03-0.46). The other HRs for developing ICC remained similar 
(Supplementary table S1). Advanced WHO clinical stage of HIV/AIDS at ART initiation (stage 4 versus 
1, adjusted HR 1.95, 95% CI 1.17-3.24) was a risk factor for incident ICC, and women who initiated ART 
at the age of 36-45 years were at highest risk of developing ICC (36-45 years versus 18-25 years, 
adjusted HR 2.51, 95% CI 1.07-5.88). A similar pattern was observed for current age with younger and 
older women having a lower risk of developing ICC compared to women aged 36-45 years (data on 
file). Women with PI-based first-line regimens (97% lopinavir/ritonavir) tended to have a lower risk of 
developing ICC than women who received a standard NNRTI-based first-line regimen (adjusted HR 
0.54, 95% CI 0.22-1.34). Using multiple imputations for missing data on CD4 cell counts and WHO 
clinical stage of HIV/AIDS at ART initiation confirmed the findings of the complete cases analysis 
(Supplementary table 2).  
 
Discussion 
 
The risk of developing ICC in women who initiated ART at the TLC in Johannesburg, South Africa, 
declined over calendar time of ART initiation with the introduction and expansion of Pap-based cervical 
cancer screening and treatment of cervical lesions. However, the ICC incidence rate in HIV-positive 
women on ART remained high even after the expansion of Pap-based cervical cancer screening to other 
HIV clinics in the area. We found that advanced WHO clinical stage of HIV/AIDS at ART initiation was a 
risk factor for developing ICC. In contrast, time since ART initiation and nadir, baseline, or current CD4 
cell counts were not associated with the risk of developing ICC.  
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This study is one of the first to describe ICC incidence rates along with associated risk factors in HIV-
positive women who initiated ART in sub-Saharan Africa, and the first one to evaluate the effect of the 
introduction of a Pap-based cervical cancer screening program on ICC incidence rates in this setting. It 
is based on prospectively collected routine clinical data, and ICC ascertainment was improved through 
record linkage with the South African NCR. However, several limitations need to be addressed. Even 
after the record linkage with the pathology-based NCR, ascertainment of ICC cases is likely to be 
incomplete, resulting in an underestimation of the ICC risk in women who initiated ART. Lag times in 
cancer registration at the NCR might lead to some under-reporting of ICC cases in more recent calendar 
periods. The results we report for HIV-positive women attending one urban ART program in South 
Africa might not necessarily be generalizable to all HIV-positive women initiating ART in South Africa 
or to other ART programs with different cervical cancer screening practices. Cervical cancer screening 
and treatment status at patient-level was not available, and therefore we could not assess the effect 
of Pap-based cervical cancer screening on ICC incidence rates directly. Data on several potentially 
relevant risk factors like HIV RNA load, number of pregnancies, contraceptive use, number of sexual 
partners, and condom use, were very limited or not available, and could therefore not be analysed. 
We assumed that women remained on ART once initiated and did not consider treatment interruptions 
and terminations. ICC incidence rates in women who are fully adherent to ART might be lower than 
what we report.  
We found that the ICC incidence rate in our cohort decreased over calendar periods of ART initiation 
with the introduction of a screening program and early treatment of cervical lesions. We are not aware 
of other studies assessing ICC incidence rates before and after the introduction of a cervical cancer 
screening program in an ART program. However, Shiels and colleagues showed that in HIV-positive 
women in the United States yearly ICC incidence rates declined steeply in the early 1990’s before the 
advent of ART.26 This decline is most likely attributable to cervical cancer screening and improved 
treatment of pre-cancerous cervical lesions.27 Other studies in HIV-positive women, on the other hand, 
showed increasing ICC incidence rates over calendar periods.28–30  
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Our study found a very high overall ICC incidence rate of more than 500/100,000 pys in HIV-positive 
women who initiated ART. Few other studies reported similarly high ICC incidence rates in HIV-positive 
women,26,28,31 but most studies found substantially lower ICC incidence rates.19–22,29,32–36 For example, 
in a cohort of regularly Pap-screened HIV-positive women in the United States, the ICC incidence rate 
was as low as 12/100,000 pys.36 Whereas well-established systematic screening programs might partly 
explain the lower ICC incidence rates in HIV-positive women living in high-income countries, the very 
low ICC incidence rates found in three sub-Saharan African record linkage studies are likely to be 
underestimations.19–21 The more limited access to pathology services in Nigeria, Uganda, and Malawi  
compared to South Africa might have resulted in more extensive under-diagnosis and under-reporting 
of ICC cases.37 In general, ICC incidence rate estimates across studies need to be compared cautiously 
due to different study populations, settings, calendar periods, and study designs.  
Immunodeficiency measured as low CD4 cell count is the most extensively studied risk factor for ICC 
in HIV-positive women, and its impact on ICC risk remains controversial. We and others did not find an 
association with ICC risk,29,38 whereas some studies showed an increased ICC risk with lower CD4 cell 
counts at cohort enrolment33 or during follow-up.34 Interestingly, we found that advanced WHO clinical 
stage of HIV/AIDS as a measure of immunodeficiency at ART initiation was a risk factor for developing 
ICC, but Mbulaiteye and colleagues did not find such an association.20 As in other studies, we also 
observed that ICC risk was highest in middle-aged women.20,33,34 In our analysis, women who received 
PI-based regimens tended to have a lower risk of developing ICC than women who received a standard 
NNRTI-based regimen. In vitro studies have suggested that some PIs might have anti-tumour effects 
against cervical cancer cells.39,40 However, as the treatment allocation was not randomized in our 
study, this finding should be interpreted with caution.  
Before cervical cancer screening was introduced at TLC ICC incidence rates in HIV-positive women who 
had initiated ART were very high. After the introduction of cervical cancer screening and early 
treatment of cervical lesions at the TLC and expansion to other HIV clinics in the area ICC risk declined. 
We did not observe a decline in ICC incidence rates by time since ART initiation. However, most women 
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in our cohort initiated ART at low CD4 cell counts, and the follow-up time of our study might not have 
been long enough to detect a protective effect of ART on ICC development.15 Besides efforts to grant 
universal access to prompt ART initiation, effective and wide-spread cervical cancer screening 
programs are needed to lower ICC-related morbidity and mortality. Different screening approaches 
including Pap smears, HPV testing, and visual inspection with acetic acid and Lugol’s iodine are 
available.41 To determine the best screening approach for a given setting, available resources and cost-
effectiveness need to be taken into account.42 Irrespective of the screening method chosen, adequate 
infrastructure, trained personnel, and access to early treatment of cervical lesions are essential to 
ensure effectiveness.43 In addition, rigorous monitoring of cervical cancer screening programs is 
needed to continuously improve and maintain patient outcomes.43  
Large-scale studies analysing temporal trends in ICC incidence rates are important because they have 
sufficient power to evaluate ICC directly as the outcome of interest. However, without patient-level 
data on screening and treatment of cervical lesions, it is not possible to determine the extent to which 
interventions such as a screening program have directly impacted on outcomes, nor to understand 
observed ICC incidence rates in context, and to prioritize targets for further intervention. Therefore, 
observational HIV cohorts routinely collecting patient-level data on cervical cancer screening status 
and treatment of cervical lesions can offer critical evidence towards understanding ICC and should be 
prioritised in future evaluations. 
With the implementation of a Pap-based screening program and improved access to treatment of 
cervical lesions the incidence rate of ICC substantially decreased in HIV-positive women who initiated 
ART. However, the risk of developing ICC after ART initiation remained high. To inform ICC prevention 
and care for HIV-positive women, implementation and thorough monitoring of cervical cancer 
screening programs in sub-Saharan Africa are essential.   
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Table 1:  Invasive cervical cancer (ICC) incidence rates per 100,000 person-years and hazard ratios 
for developing ICC in HIV-positive women who initiated ART. 
 Patients 
(N) 
Person- 
years 
Cases 
 (N) 
Incidence rate  
(95% CI) 
Crude HR 
(95% CI) 
Adjusted HR *† 
(95% CI) 
Overall 10,640 27,257 138 506 (428-598) - - 
Calendar period of 
ART start 
      
   04/2004-03/2005 1,236 5,853 36 615 (444-853) 1.00 1.00 
   04/2005-12/2008 5,296 16,794 90 536 (436-659) 0.81 (0.54-1.20) 0.82 (0.53-1.26) 
   01/2009-08/2011 4,108 4,609 12 260 (148-458) 0.37 (0.19-0.74) 0.42 (0.20-0.87) 
Calendar period of 
follow-up 
      
   04/2004-03/2005 - 492 0 0 (0-752) - - 
   04/2005-12/2008 - 11,394 64 562 (440-718) 1.00 - 
   01/2009-08/2011 - 15,371 74 481 (383-605) 0.84 (0.58-1.21) - 
Time since ART 
start 
      
   0-1 year - 8,689 41 472 (347-641) - - 
   >1-3 years - 10,936 56 512 (394-665) - - 
   >3 years - 7,633 41 537 (396-730) - - 
Age at ART start       
  18-25 years 1,064 2,695 6 223 (100-496) 1.00 1.00 
  26-35 years 4,693 12,610 64 508 (397-648) 2.28 (0.99-5.26) 1.93 (0.83-4.48) 
  36-45 years 3,290 8,293 53 639 (488-837) 2.89 (1.24-6.72) 2.51 (1.07-5.88) 
  ≥ 46 years 1,593 3,658 15 410 (247-680) 1.86 (0.72-4.79) 1.35 (0.50-3.63) 
Employment status       
  Unemployed 5,646 15,064 81 538 (432-669) 1.00 - 
  Employed 4,765 11,801 55 466 (358-607) 0.86 (0.61-1.22) - 
  Missing 229 391 2 - - - 
BMI at ART start 
[kg/m2] 
      
  < 18.5 1,432 3,347 15 448 (270-743) 1.00 - 
  18.5-24.9 4,899 13,252 67 506 (398-642) 1.13 (0.65-1.98) - 
  ≥ 25.0 3,250 8,440 46 545 (408-728) 1.22 (0.68-2.19) - 
  Missing 1,059 2,218 10 - - - 
Smoking status       
  Never smoked 8,823 23,003 117 509 (424-610) 1.00 - 
  Ever smoked 506 1,192 7 587 (280-1232) 1.15 (0.54-2.47) - 
  Missing 1,311 3,062 14 - - - 
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First-line ART 
regimen 
      
   NNRTI-based 9,785 24,637 129 524 (441-622) 1.00 1.00 
   PI-based 824 2,535 6 237 (106-527) 0.45 (0.20-1.1) 0.54 (0.22-1.34) 
   Other ART 31 85 3 3533 (1139-10953) 6.75 (2.15-21.21) 7.85 (1.93-32.03) 
WHO stage of HIV/ 
AIDS at ART start 
      
   1 3,878 11,128 53 476 (364-623) 1.00 1.00 
   2 1,738 3,999 17 425 (264-684) 0.90 (0.52-1.55) 0.88 (0.51-1.53) 
   3 2,534 6,929 35 505 (363-704) 1.06 (0.69-1.62) 0.99 (0.64-1.52) 
   4 1,021 2,208 21 951 (620-1459) 1.99 (1.20-3.31) 1.95 (1.17-3.24) 
   Missing 1,469 2,992 12 - - - 
CD4 cell count at 
ART start [cells/µl] 
      
   < 50 2,522 6,644 36 542 (391-751) 1.00 - 
  50-99 1,777 4,937 25 506 (343-749) 0.94 (0.56-1.56) - 
  100-199 3,430 8,981 48 534 (403-709) 0.99 (0.64-1.52) - 
  ≥ 200 1,857 3,904 19 487 (310-763) 0.91 (0.52-1.58) - 
  Missing 1,054 2,790 10 - - - 
CD4 nadir [cells/µl]       
   < 50 2,947 7,840 47 599 (450-798) 1.00 - 
  50-99 2,092 5,887 26 442 (301-649) 0.74 (0.46-1.19) - 
  100-199 3,932 10,307 50 485 (368-640) 0.81 (0.54-1.21) - 
  ≥ 200 1,594 3,166 15 474 (286-786) 0.79 (0.44-1.42) - 
  Missing 75 57 0 - - - 
Current CD4 cell 
count [cells/µl] 
      
  < 100 - 2,429 15 618 (372-1024) 1.00 - 
  100-199 - 4,379 21 480 (313-735) 0.81 (0.41-1.60) - 
  200-349 - 7,621 43 564 (418-761) 0.92 (0.47-1.78) - 
  350-499 - 6,189 26 420 (286-617) 0.65 (0.31-1.35) - 
  ≥ 500 - 6,182 31 501 (353-713) 0.75 (0.36-1.58) - 
  Missing - 457 2 - - - 
Haemoglobin  at 
ART start [g/dl] 
      
  < 10.0 2,589 6,014 27 449 (308-655) 1.00 - 
  10.0-11.9 3,561 9,288 49 528 (399-698) 1.18 (0.74-1.89) - 
  ≥ 12.0 3,570 9,512 52 547 (417-717) 1.22 (0.77-1.95) - 
  Missing 920 2,442 10 - - - 
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* Restricted to 9,171 women with available WHO clinical stage of HIV/AIDS at ART start. 
† Adjusted for age, calendar period of ART start, first-line ART regimen, and WHO clinical stage of 
HIV/AIDS. 
ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; ICC, invasive cervical 
cancer; IQR, interquartile range; HR, hazard ratio; NNRTI, non-nucleoside reverse-transcriptase 
inhibitors; PI, protease-inhibitors; WHO, World Health Organization. 
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Figure 1: Identification of study population. The flow diagram shows the number of included and 
excluded women.  
 
ART, antiretroviral therapy; ICC, invasive cervical cancer. 
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Figure 2: Invasive cervical cancer incidence rates with 95% confidence intervals by time since 
initiation of antiretroviral therapy.  
 
ART, antiretroviral therapy; ICC, invasive cervical cancer; pys; person-years. 
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years and hazard ratios for developing ICC in HIV-positive women on ART. Sensitivity 
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including those diagnosed with ICC within that time period.  
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Supplementary Table S1:  Invasive cervical cancer (ICC) incidence rates per 100,000 person-years 
and hazard ratios for developing ICC in HIV-positive women on ART. Sensitivity analysis excluding all 
women with less than six months of follow-up after ART initiation, including those diagnosed with 
ICC within that time period.  
 Patients  
(N) 
Person- 
years  
Cases 
 (N) 
Incidence rate  
(95% CI) 
Crude HR 
(95% CI) 
Adjusted HR *† 
(95% CI) 
Overall 8,560 22,588 112 496 (412-597) - - 
Calendar period of 
ART start 
      
   04/2004-03/2005 1,102 5,278 35 663 (476-924) 1.00 1.00 
   04/2005-12/2008 4,513 14,414 75 520 (415-652) 0.72 (0.47-1.08) 0.69 (0.44-1.07) 
   01/2009-08/2011 2,945 2,896 2 69 (17-276) 0.09 (0.02-0.39) 0.11 (0.03-0.46) 
Calendar period of 
follow-up 
      
   04/2004-03/2005 - 64 0 - - - 
   04/2005-12/2008 - 9,020 49 543 (411-719) 1.00 - 
   01/2009-08/2011 - 13,504 63 467 (364-597) 0.82 (0.54-1.23) - 
Time since ART 
start 
      
   0.5-1 year - 4,020 15 373 (225-619) - - 
   >1-3 years - 10,936 56 512 (394-665) - - 
   >3 years - 7,633 41 537 (396-730) - - 
Age at ART start       
  18-25 years 826 2,238 5 223 (93-537) 1.00 1.00 
  26-35 years 3,807 10,539 54 512 (392-669) 2.30 (0.92-5.75) 1.94 (0.77-4.89) 
  36-45 years 2,669 6,844 43 628 (466-847) 2.83 (1.12-7.15) 2.52 (0.99-6.42) 
  ≥ 46 years 1,258 2,967 10 337 (181-626) 1.53 (0.52-4.48) 1.12 (0.36-3.47) 
Employment status       
  Unemployed 4,491 12,598 68 540 (426-685) 1.00 - 
  Employed 3,914 9,690 42 433 (320-587) 0.80 (0.55-1.18) - 
  Missing 155 300 2 - - - 
BMI at ART start 
[kg/m2] 
      
  < 18.5 1,040 2,756 13 472 (274-813) 1.00 - 
  18.5-24.9 4,063 11,062 54 488 (374-637) 1.04 (0.57-1.90) - 
  ≥ 25.0 2,706 6,979 37 530 (384-732) 1.13 (0.60-2.13) - 
  Missing 751 1,792 8 - - - 
Smoking status       
  Never smoked 7,184 19,104 96 502 (411-614) 1.00 - 
  Ever smoked 378 977 5 512 (213-1230) 1.02 (0.41-2.51) - 
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  Missing 998 2,507 11 - - - 
First-line ART 
regimen 
      
   NNRTI-based 7,870 20,345 104 511 (422-619) 1.00 1.00 
   PI-based 664 2,172 6 276 (124-615) 0.53 (0.23-1.21) 0.66 (0.26-1.66) 
   Other ART 26 71 2 2824 (706-11291) 5.52 (1.36-22.39) 10.52 (2.56-43.32) 
WHO clinical stage 
of HIV/AIDS  at ART 
 
      
   1 3,277 9,377 42 448 (331-606) 1.00 1.00 
   2 1,413 3,230 13 402 (234-693) 0.91 (0.49-1.69) 0.90 (0.48-1.67) 
   3 2,023 5,821 30 515 (360-737) 1.15 (0.72-1.83) 1.08 (0.67-1.73) 
   4 738 1,794 18 1003 (632-1592) 2.25 (1.29-3.90) 2.25 (1.29-3.93) 
   Missing 1,109 2,366 9 - - - 
CD4 cell count at 
ART start [cells/µl] 
      
   < 50 1,954 5,572 31 556 (391-791) 1.00 - 
  50-99 1,463 4,150 21 506 (330-776) 0.91 (0.53-1.59) - 
  100-199 2,823 7,450 38 510 (371-701) 0.92 (0.57-1.48) - 
  ≥ 200 1,480 3,086 14 454 (269-763) 0.83 (0.44-1.56) - 
  Missing 840 2,330 8 - - - 
CD4 nadir [cells/µl]       
   < 50 2,306 6,578 41 623 (459-846) 1.00 - 
  50-99 1,735 4,957 22 444 (292-674) 0.71 (0.43-1.20) - 
  100-199 3,253 8,545 38 445 (324-611) 0.72 (0.46-1.11) - 
  ≥ 200 1,250 2,469 11 445 (247-804) 0.73 (0.37-1.42) - 
  Missing 16 38 0 - - - 
Current CD4 cell 
count [cells/µl] 
      
  < 100 - 939 7 746 (356-1564) 1.00 - 
  100-199 - 2,882 13 451 (262-777) 
 
0.57 (0.23-1.44) - 
  200-349 - 6,657 37 556 (403-767) 0.65 (0.29-1.47) - 
  350-499 - 5,932 24 405 (271-604) 0.45 (0.19-1.06) - 
  ≥ 500 - 6,052 31 512 (360-728) 0.56 (0.24-1.32) - 
  Missing - 126 0 - - - 
Haemoglobin  at 
ART start [g/dl] 
      
  < 10.0 1,905 4,943 22 445 (293-676) 1.00 - 
  10.0-11.9 2,920 7,711 38 493 (359-677) 1.11 (0.66-1.88) - 
  ≥ 12.0 3,019 7,890 42 532 (393-720) 1.20 (0.72-2.01) - 
  Missing 716 2,044 10 - - - 
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* Restricted to 7,451 women with available WHO clinical stage of HIV/AIDS at ART start. 
† Adjusted for age, calendar period of ART start, first-line ART regimen, and WHO clinical stage. 
ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; ICC, invasive cervical 
cancer; IQR, interquartile range; HR, hazard ratio; NNRTI, non-nucleoside reverse-transcriptase 
inhibitors; PI, protease-inhibitors; WHO, World Health Organization. 
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Supplementary Table S2: Hazard ratios for developing ICC in HIV-positive women who initiated 
ART. Sensitivity analysis based on multiply imputed dataset. 
* Adjusted for age, calendar period of ART start, first-line ART regimen, and WHO clinical stage of 
HIV/AIDS. 
ART, antiretroviral therapy; CI, confidence interval; ICC, invasive cervical cancer; HR, hazard ratio; 
NNRTI, non-nucleoside reverse-transcriptase inhibitors; PI, protease-inhibitors; WHO, World Health 
Organization. 
 
 
 Crude HR (95% CI) Adjusted HR * (95% CI) 
Calendar period of ART start   
   04/2004-03/2005 1.00 1.00 
   04/2005-12/2008 0.81 (0.54-1.20) 0.79 (0.53-1.18) 
   01/2009-08/2011 0.37 (0.19-0.74) 0.35 (0.18-0.71) 
Age at ART start   
  18-25 years 1.00 1.00 
  26-35 years 2.28 (0.99-5.26) 2.15 (0.93-4.97) 
  36-45 years 2.89 (1.24-6.72) 2.66 (1.14-6.21) 
  ≥ 46 years 1.86 (0.72-4.79) 1.71 (0.66-4.45) 
First-line ART regimen   
   NNRTI-based 1.00 1.00 
   PI-based 0.45 (0.20-1.1 0.50 (0.22-1.15) 
   Other ART 6.75 (2.15-21.21) 7.33 (2.31-23.27) 
WHO stage of HIV/AIDS at ART start   
   1 1.00 1.00 
   2 0.91 (0.53-1.57) 0.89 (0.52-1.54) 
   3 1.09 (0.72-1.65) 1.01 (0.66-1.55) 
   4 1.93 (1.17-3.19) 1.87 (1.13-3.12) 
CD4 cell count at ART start [cells/µl]   
   < 50 1.00 - 
  50-99 0.93 (0.56-1.56) - 
  100-199 1.00 (0.65-1.55) - 
  ≥ 200 0.93 (0.53-1.61) - 
